Search
NVIDIA is collaborating with multiple medical and research institutions worldwide to advance research in protein design, drug discovery, and cancer treatment. In partnership with the Institute for Protein Design at the University of Washington School of Medicine, it has released the open model RFD4-Proteina to support researchers in generating and screening candidate proteins. Meanwhile, Siemens Healthineers is jointly developing next-generation adaptive radiotherapy technology with NVIDIA, utilizing AI agents for collaborative treatment. Additionally, companies such as Benchling and Danaher are developing research AI agents based on NVIDIA's BioNeMo platform to optimize drug design and automate laboratory and biological research processes.
-
C114 Communication Network -
Communication Home
